Jul. 24 at 5:28 PM
$VNDA Hell, I don't know guys. If they get approval for Charcot-Marie-Tooth disease in 2029 they will get a voucher they can sell for probably
$200 million. That is a long time away when you are burning
$50 million per quarter flying planes with banners to sell your existing drugs at a loss. There is potential here but there is danger. We can't see everything but I still have a gut feeling things are going to get worse before they start improving. I am thinking we have another dollar or so to go down and it may well spike below that but should stabilize at
$4 to
$4.25. Possibly the CEO will step in again and buy another 10,000 to 30,000 shares at that price like he did before. There should be a climb in price in November as people speculate for the December approval of Imsidolimab. Should be good for a double from
$4.25. Always the chance of a magic buyout at anytime since they do have a pipeline.
